It has been hypothesized that neural reactivity to drug cues in certain limbic/paralimbic regions of the brain is an indicator of addiction severity and a marker for likelihood of success in treatment. To address this question, in the current study, 32 participants (44 percent female) completed a functional magnetic resonance imaging cigarette cue exposure paradigm 2 hours after smoking, and then enrolled in a 9-week smoking cessation treatment program. Neural activation to smoking cues was measured in five a priori defined limbic/paralimbic regions previously implicated with cue reactivity across substances. These included regions of the ventral striatum, anterior cingulate cortex and amygdala. Cox proportional hazard modeling was conducted to predict the number of days to first smoking lapse by using neural activation in these regions. Greater neural activation during pre-treatment exposure to smoking cues in the right ventral striatum, the left amygdala, and the anterior cingulate was associated with longer periods of abstinence following cessation. A similar pattern was present for continuous abstinence for the full duration of treatment. While baseline levels of nicotine dependence were strongly associated with treatment outcome, activation in the right ventral striatum predicted duration of abstinence beyond level of nicotine dependence. These results suggest that pre-treatment reactivity to smoking cues in areas associated with cue reactivity may be associated with successfully maintaining abstinence during treatment. This is consistent with models that propose that as addiction becomes more severe, motivational processing shifts from regions that subserve reward salience and learning to regions responsible motor behavior and habit learning.
INTRODUCTION
Smoking-related illness remains the leading preventable cause of death in the United States (National Institute on Drug Abuse 2014). Success rates for quitting smoking rarely exceed 25 percent at 6 months following treatment with the best evidence-based approaches (American Cancer Society 2014) . Identifying pre-treatment correlates of response to treatment may eventually be useful for assessment of relapse risk and to determine individualized treatment plans for smoking cessation. Additionally, understanding causes of treatment failure may help to enhance understanding of nicotine dependence.
found a number of cortical regions to be activated in response to smoking cues, including the dorsolateral prefrontal cortex, the medial frontal cortex, the posterior cingulate cortex, cuneus, precuneus and lingual gyrus (Engelmann et al. 2012) . However, another meta-tanalysis focused on CR across different addictive substances, including smoking, indicated that an interconnected group of limbic/paralimbic regions of the brain, specifically the ventral striatum, amygdala and anterior cingulate cortex (ACC), is mostly strongly associated with CR (Kühn & Gallinat 2011) . These limbic/paralimbic regions are closely connected to the mesolimbic dopamine system, which is critical to the reinforcing experience of addictive drugs and has been referred to as the 'final common pathway' of all reinforcing drugs (Pierce & Kumaresan 2006) . Two alternative models have been proposed to explain how these regions' responsiveness to drug cue exposure relates to addiction severity and relapse risk. The incentive sensitization theory of addiction posits that as an individual becomes more severely addicted to a drug, neuroadaptive changes take place that create an augmented state of 'wanting' the drug, characterized by a shift to greater responding to drug cues in areas of the brain associated with incentive salience such as the nucleus accumbens (Robinson & Berridge 1993 , 2001 . This state is putatively independent of changes in drug 'liking'. An alternate model, referred to as the incentive-habit model, suggests that less addicted drug users will experience greater response to the presence of drug cues in these incentive salience brain regions, while the most addicted individuals primarily consume drugs in response to habitual and biological factors (such as blood nicotine levels) rather than in response to cues that trigger craving. This reflects a transition from ventral striatal processing of incentive learning (nucleus accumbens) to dorsal striatal processing of habit learning as an individual becomes more severely addicted (Mogg, Field & Bradley 2005; Everitt & Robbins 2013) . Studies in nicotine-dependent smokers have used self-report measures of nicotine dependence and their association with response in these brain regions during exposure to smoking cues to empirically test these two models. However, the results have been mixed, with some studies indicating that greater neural activation in response to smoking cues in is associated with more severe nicotine dependence (e.g. McClernon, Kozink & Rose 2008) and others finding attenuated neural response to cues to be a sign of more severe dependence (e.g. Vollstädt-Klein et al. 2011) .
Two studies have suggested that neural response in the limbic/paralimbic brain regions highlighted by Kühn & Gallinat (2011) may also be associated with outcome in smoking cessation treatment, specifically that heightened neural response in these regions during cue exposure predicts failure in smoking cessation treatment (Janes et al. 2010; Versace et al. 2014) . In one study, 21 nicotine-dependent women performed a functional magnetic resonance imaging (fMRI) CR procedure prior to nicotine replacement therapy and a manualized behavioral smoking cessation intervention (Janes et al. 2010) . The participants were grouped based on treatment success, and their pre-treatment neural activity was compared by using a whole-brain, voxelwise analysis. Results indicated that response to cues was greater in the insula, dorsolateral prefrontal cortex, posterior cingulate, parahippocampal gyrus, putamen, thalamus and cerebellum in the participants who lapsed at any point during a subsequent 9-week smoking cessation treatment. The second study took a different approach, using cluster analysis to divide 55 pre-quit attempt smokers into two groups based on their neural response to smoking cues relative to pleasant images in an visual activation network (i.e. cuneus, precuneus, middle and inferior occipital gyri, superior parietal lobule, middle temporal gyrus and fusiform gyri; Versace et al. 2011) . Abstinence rates were compared between these groups following 8 weeks of smoking cessation treatment with the group showing greater response in the visual network to pleasant images relative to smoking images being more likely to be abstinent following treatment. Follow-up voxelwise analyses revealed that the two groups also differed in activation in the right dorsal striatum, dorsomedial prefrontal cortex and right dorsolateral prefrontal cortex.
These two studies provide preliminary evidence that an individual's neural response in limbic/paralimbic regions to smoking cues may be a marker of smoking cessation treatment prognosis. However, the studies used different designs and statistical analyses, and neither was explicitly designed to test these regions; one study found greater activation in the putamen predicted lapse as part of an exploratory whole-brain voxelwise approach (Janes et al. 2010) , and the other focused on differences in activation in the visual system between pleasant images and smoking cues and, as a follow-up analysis, found differences in dorsal striatum activation between groups formed according to activity in the visual system (Versace et al. 2014) . A priori testing of only the regions shown to be most consistently activated by exposure to smoking (and other drug) cues would more conclusively address the possibility that response in these regions to smoking cues is a predictor of treatment outcome. It would also contribute to understanding the role of these regions in addiction to nicotine.
Thus, the goal of the current study was to test the hypothesis that neural reactivity to smoking cues specifically in the ventral striatum, the amygdala and the anterior cingulate cortex serves as an indicator of lapse and continuous abstinence in smoking cessation treatment (Kühn & Gallinat 2011) . A focus on the limbic/paralimbic regions highlighted by Kühn & Gallinat (2011) was chosen to reduce the number of tests conducted and to explicitly focus on the core motivational systems, which are the basis of the two competing models discussed in the preceding texts (incentive sensitization and incentive habit). While a broader focus encompassing other neural systems involved in drug craving could have been used to obtain a more comprehensive picture of the prediction of lapse with brain activity during a CR paradigm (such as using the regions found in Engelmann et al. 2012) , we elected to focus on a small set of regions that subserve common function to maximize power while avoiding excessive statistical tests. We hypothesized that the five regions identified by Kuhn and Gallinat would be most associated with CR across all substances (right and left ventral striatum, caudal and rostral anterior cingulate cortex and amygdala) and would significantly be associated with the duration participants remained abstinent after cessation in an organized smoking cessation program. In addition to its use of regions of interest (ROIs) defined a priori from prior meta-analytic research as predictors, this study differed from previous studies its focus on the contrast of images of smoking cues with neutral images and the use of a continuous measure of first lapse in treatment.
MATERIALS AND METHODS

Participants
Right-handed treatment-seeking smokers were recruited from the community by using advertisements. Participants were required to be 18-60 years old, to smoke at least 10 cigarettes per day and to report a motivation to quit of at least 5 on a scale of 1 to 10. Exclusionary criteria included major medical, psychiatric or neurologic disorders; average consumption of more than six alcoholic beverages per day over the previous year; use of marijuana more than weekly over the previous 3 months; use of any other psychoactive drugs more than monthly over the previous 3 months; MRI contraindications; and IQ of less than 70. Of 52 participants who completed the initial fMRI assessment, one participant's data was lost due to a data transfer error, five were excluded for moving more than 0.35 mm during at least 33 percent of the brain volume acquisitions (i.e. excessive movement), and 14 did not initiate a quit attempt. Thus, 32 participants were included in the final analysis. The final sample is described in Table 1 .
Procedures
All procedures were approved by the University of Georgia Institutional Review Board and were in compliance with the declaration of Helsinki. The participants were first screened by telephone to assess inclusion and exclusion criteria. Those with a positive screen were invited for an in-person eligibility assessment at which point smoking behavior was confirmed by using exhaled carbon monoxide. Participants who met the inclusion and exclusion criteria were scheduled for an fMRI assessment session. To standardize exposure and rule out severe withdrawal effect, the participants were instructed to smoke immediately prior to arriving for the session. Following an hour of pre-scan assessment and training, the participants completed a 90-minute MRI protocol consisting of the CR procedure, an anatomical scan and other fMRI paradigms that are not the focus of the current report. Throughout this period, the participants were not allowed to smoke and the CR procedure was conducted approximately 2 hours after the participants smoked their last cigarette. Baseline craving ratings taken immediately prior to the CR paradigm indicate that the participants were in a state of moderate deprivation during the CR procedure, endorsing slightly above 50 percent of the scale max on average (see Wilson & Sayette 2015 for a review of the role of deprivation in fMRI CR procedures).
Following these sessions, the participants completed a 9-week smoking cessation treatment protocol that combined in-person individual counseling sessions with a therapist and nicotine replacement therapy. A 90-minute treatment planning session was set approximately 1 week after the MRI protocol with a quit date being scheduled 1 week after that. The participants met individually with their smoking cessation therapist for 60 minutes on their quit date and then for 30 minutes weekly for the remainder of treatment. Thus, the total duration of treatment was one 90-minute session, one 60-minute session and seven 30-minute sessions. The nine weekly counseling sessions followed evidence-based recommendations (Fiore et al. 2008) and comprised a motivational interviewing approach (e.g. engaging with clients, evoking indivdiual motivation for quitting and facilitating change talk; Miller & Rollnick 2003) , with elements of cognitive behavioral therapy (e.g. identifying antecedents of smoking and managing high-risk situations). The therapy manual and protocol adherence checklists are included in Supporting Information. Nicotine replacement was provided in the form of the nicotine patch with dosing following the manufacturer's instructions (4 weeks 21 mg, 2 weeks 14 mg and 2 weeks 7 mg) and initiated on the quit date. The participants were paid for pre-treatment and posttreatment research visits but were not paid for treatment visits, which were provided without cost. Treatment was provided by trained masters-level clinicians supervised by a licensed clinical psychologist. Therapy sessions were manualized and coded by another therapist for fidelity to the protocol by using a checklist developed for the treatment manual and for compliance with principles of motivational interview by using the Global Rating of Motivational Interviewing Therapist (Moyers 2004). Seventy-five percent of the initial therapy sessions and 66 percent of the second therapy sessions were coded for adherence to the treatment protocol, indicating 99 percent adherence to the stated protocol in sessions 1 and 2. Additionally, 59 percent of sessions 1 through 9 were coded for adherence to principles of motivational interviewing, indicating that adherence to motivational interviewing principles among therapists was 96 percent of scale maximum.
fMRI protocol
Imaging data were collected with a General Electric 16-channel fixed-site Signa HDx 3.0 Tesla MRI scanner. Structural images were acquired for anatomical reference by using a high-resolution T1 SPGR sequence (voxel size = 1 mm 3 , a field of view = 256 2 mm, matrix = 256 2 and axial slice thickness = 1 mm). Sufficient contiguous axial slices were acquired to obtain whole-brain coverage. Functional imaging used T2* echo planar imaging with a single-shot gradient echo pulse sequence (TR = 2500 ms, TE = 25 ms, field of view = 225 2 mm, matrix = 64 2 , with 40 contiguous 3.5 mm slices collected axially, isometric voxel size = 3.5 mm 3 ). Two imaging runs of 215 and 220 brain volumes were acquired.
fMRI cue reactivity procedure
The CR procedure consisted of two imaging runs lasting 430 and 440 seconds during which participants viewed four blocks of smoking images (40 seconds per block), four blocks of neutral images (40 seconds per block), four blocks of rest (fixation cross presented for 20 seconds per block) and craving rating screens (10 seconds per block). Craving was rated three times: at the beginning and end of the experiment and once between the two imaging runs. Smoking and neutral blocks contained eight images that were presented for 5 seconds each in immediate succession. The order of these blocks was counterbalanced across runs. Smoking and neutral cue pictures were drawn from a set of pictures that has been used previously in fMRI smoking CR research (McClernon et al. 2005; McClernon et al. 2007) . They included images of cigarettes and people smoking. Neutral cue pictures included everyday objects (e.g. pencils and stapler), and people engaged in everyday activities (e.g. using the telephone). The participants were instructed to pay attention to the photographs on the screen and (when prompted) rate their craving for cigarettes. Prior to the scanning procedure, the participants were instructed verbally how to use an MRI compatible button box to rate their craving for cigarettes on a scale from 0 to 8.
MEASURES
Fagerström Test of Nicotine Dependence
This six-item questionnaire was used to measure the participants' level of nicotine dependence. This measure is a widely used measure of nicotine dependence and has been shown to have good reliability and validity (Piper, McCarthy & Baker 2006) .
Treatment response
The primary outcome was the number of days following their quit date that participants did not smoke (i.e. 'days to lapse'), defined via retrospective timeline follow-back at every therapy session and confirmed by using exhaled CO measured by using a PiCO+ Smokerlyzer (Bedfont Scientific Ltd, Rochester, UK). Exhaled CO was used to confirm self-reported smoking behavior with exhaled CO of 10 parts per million or greater used to indicate current smoking (Wald et al. 1981; Deveci et al. 2004) . Smoking lapse was selected as the outcome of interest due to its consistent association with long-term treatment outcomes (Brandon et al. 1990; Kenford et al. 1994; Shiffman et al. 1996) and use of total abstinence (i.e. absence of lapse) by Janes et al. (2010) in a previous study investigating neural response to a CR paradigm with smoking cessation treatment response. In order to maximize power, lapse was measured continuously as number of days to lapse, although continuous abstinence throughout treatment was also assessed for continuity with prior literature (i.e. Janes et al. 2010) . Participants who dropped out of treatment following their quit date or had exhaled CO ≥ 10 were considered to have lapsed, and participants who did not lapse were coded as the total number of days assessed following their quit date.
ANALYSES
Data processing
Functional magnetic resonance imaging data processing and analysis was conducted by using Analysis of Functional NeuroImages software (Cox 1996) as a block design experiment. Functional dataset volumes were registered and individually aligned to T1 anatomical datasets (corrected for head movement). Volumes including movement greater than 0.35 mm (i.e. 1/10 voxel) along the x, y or z axes were censored from analyses, and participants with greater than 33 percent of volumes censored were excluded from the study. Following motion correction, datasets were transformed into Talairach space (Talairach & Tournoux 1988) and individual volumes from each run were registered to a base volume (i.e. third volume of the first CR imaging run; Saad et al. 2009 ). The data were masked to exclude voxels outside the brain and spatially smoothed by using a 7-mm (i.e. two voxels) full width half maximum Gaussian filter. Raw BOLD signal was scaled to percent signal change from mean signal intensity. For functional datasets, a GLM was completed by using regressors relating to condition (smoking pictures and neutral pictures) and six nuisance regressors to account for motion (x, y, z, roll, pitch and yaw), as well as regressors for linear, quadratic and cubic trends. The passive rest condition was not modeled and therefore served as a baseline.
Data analysis
To test the hypothesis that the limbic/paralimbic regions associated with CR across substances would predict smoking cessation treatment outcomes, a 4 mm radius sphere (268mm 3 ) was drawn centered on the coordinates provided for each of the five limbic/paralimbic regions found to be associated with CR in the metaanalysis by Kühn & Gallinat (2011) . The Analysis of Functional NeuroImages ROI draw plug-in was used to translate MNI coordinates to Talairach space. The regions from this paper were the left and right ventral striatum, the left amygdala and two regions of the ACC that crossed the midline (Figure 1) . Then, the average beta value of the contrast of smoking and neutral images in each sphere was calculated for each participant. For the primary hypothesis tests, Cox proportional hazard regression analyses were conducted at the group level to determine if average beta values in these ROIs were associated with days to lapse. To provide an assessment of longer term lapse, continuous abstinence categorically defined (lapsed at all versus did not lapse at all) was also tested as an outcome measure by using logistic regression. For Cox and logistic regression models, independent variables were standardized to improve interpretability of results (i.e. no effect = hazard ratio of 1). Subsequently, as a follow-up analysis to clarify the role of Fagerström Test of Nicotine Dependence (FTND) in this effect, each region in which response to CR was associated with days to lapse was run in a separate hierarchical Cox regression model in which FTND score was first entered into the model followed by the region of interest. This was done to determine whether neuroimaging effects contributed uniquely to outcome prediction beyond another known predictor of treatment outcome. To determine if one condition was most important in predicting lapse or indicating nicotine dependence severity by using the CR paradigm, Cox regression analyses conducted testing activation in the five ROIs during smoking cues (relative to baseline) and during neutral cues (relative to baseline) as predictors of lapse and Pearson correlations were used to assess the relationship of this activation with FTND. Using gender and age as covariates was considered but ultimately was not done as neither was significantly associated with nicotine dependence, self-reported craving or activation during the CR paradigm in ROIs.
To complement these functional neuroimaging results, Pearson's correlations were conducted among the regions tested, FTND and self-reported change in craving from before to after the CR paradigm and FTND. Self-reported craving ratings were not collected from two participants due to technical failure, and these values were mean imputed. Additionally, FTND, baseline self-reported craving (i.e. pre-scan) and change in self-reported craving in response to the CR paradigm (i.e. post-scan-pre-scan) were tested as predictors of days to lapse in independent Cox regression models.
RESULTS
Behavioral findings
The participants attended an average of 7 out of 9 treatment sessions (SD = 2.40) with 8 participants dropping out of treatment after their quit date and 15 participants completing all 9 sessions. Participants who completed all nine sessions did not differ in age, gender, race, education or income from those who did not (P > 0.1). Participants who completed all nine sessions had lower levels of nicotine dependence from those who did not (t = À2.17, P = 0.04) but did not differ on demographic variables. The participants averaged 17.5 days until first lapse (SD = 20.30) with six participants lapsing within the first 24 hours of their quit attempt and 9 participants remaining abstinent for the full 49 days of treatment. Participants who remained abstinent throughout treatment had lower levels of nicotine dependence than those who did not (t = 2.66, P = 0.01) but did not differ on any demographic characteristics (P > 0.07). In Cox regression analyses, pre-treatment nicotine dependence as measured by the FTND predicted days until lapse (hazard ratio = 2.15, P = 0.002, 95 percent CI = 1.31-3.52).
On average, the participants rated their craving to smoke prior to the first run of the CR paradigm as 4.57 out of 8 (SE = 0.42), following the first run as 4.90 (SE = 0.42) and following the second run as 5.00 (SE = 0.42). Although directionally consistent, the change from the start to end of the CR paradigm was not significant (t = 1.49, P = 0.15). Days to lapse was not predicted by self-reported craving at baseline (hazard ratio = 1.23, P = 0.32, 95 percent CI = 0.81-1.85) or following the CR procedure relative to baseline (hazard ratio = 1.03, P = 0.88, 95 percent CI = 0.70-1.52).
FUNCTIONAL NEUROIMAGING FINDINGS
In the study's primary hypothesis tests, Cox regression indicated that greater reactivity in the left amygdala, the caudal anterior cingulate and right ventral striatum significantly predicted days to lapse (Table 2) . In logistic regression, right ventral striatum (WALD = 4.97, P = 0.03, odds ratio = 4.87) and left amygdala (WALD = 4.62, P = 0.03, odds ratio = 2.76) significantly predicted whether the participants maintained continuous abstinence throughout treatment, although caudal anterior cingulate fell short of significance (WALD = 3.31, P = 0.07, odds ratio = 2.36). Neither controlling for self-reported craving prior to the CR paradigm nor change in craving during the CR paradigm altered these regions prediction of lapse.
In secondary analyses controlling for FTND, the association with days to lapse remained significant in the right ventral striatum (hazard ratio = 0.64, P = 0.05, 95 percent CI = 0.41-1.00), although not for left amygdala (hazard ratio = 0.68, P = 0.15, 95 percent CI = 0.41-1.14) or caudal anterior cingulate cortex (hazard ratio = 0.77, P = 0.20, 95 percent CI = 0.52-1.14).
Supplemental correlation analyses indicated that neither baseline craving (r = 0.32, P = 0.08) nor change in craving (r = 0.21, P = 0.25) were associated with FTND. Activity in the left amygdala during smoking cues (relative to neutral cues) was inversely associated with FTND (r = À0.41, P = 0.02; Figure 2 ). Change in craving was inversely associated with the left (r = À0.46, P = 0.009) and right ventral striatum (r = À0.46, P = 0.02) and the rostral anterior cingulate cortex (r = À0.41, P = 0.02). There were no other significant associations among the predictor regions, FTND and self-reported craving.
In supplemental Cox regression analyses investigating the importance of individual conditions in the CR paradigm to predicting lapse, in no region was activation during smoke or neutral cues relative to baseline significant as a predictor of days to lapse, suggesting that the difference between responses to smoking and neutral cues is the aspect that is associated with lapse. Activation during smoking cues (relative to baseline) in the right and left ventral striatum was significantly negatively correlated with FTND, as was activity in the right ventral striatum during neutral cues (relative to baseline). In no other regions was smoke or neutral relative to baseline significantly related to FTND.
DISCUSSION
This study examined whether pre-treatment brain reactivity to smoking cues predicted duration to first lapse in smoking cessation treatment. Specifically, we examined whether neural response to smoking cues in five limbic/paralimbic ROIs that have been shown in prior research to be activated by exposure to drug cues was associated with the number of days until lapse during an assisted cessation attempt. Greater neural response to smoking cues in the right ventral striatum, the left amygdala and the caudal ACC was significantly associated with longer duration of abstinence following quit date.
Current models suggest that the amygdala and ventral striatum are critical to the process of assigning and experiencing of emotional and motivational salience to drug cues (Kühn & Gallinat 2011) . The ACC has been associated with the cognitive modulation of emotion (Ochsner et al. 2004; Kalisch et al. 2006) . These regions are all a part of what has been described as the 'final common pathway' of drug craving (Kalivas & Volkow 2005) , which is a critical pathway to the reinforcing effects of different classes of drugs (Pierce & Kumaresan 2006) . One model of the neural response to drug cues in addiction suggests that early stage use is characterized by deliberate hedonic use and associated with greater activity in limbic/paralimbic brain regions during cue exposure, while later stage drug use is characterized by craving occurring in response to internal cues, such as withdrawal, rather than environmental cues (Everitt & Robbins 2005; Everitt et al. 2008) . The finding that increased ventral striatum, amygdala and ACC reactivity to smoking cues was associated with greater duration of short-term abstinence in smoking cessation treatment may represent further support for this interpretation: that greater reactivity in these regions associated with less difficulty quitting suggests that their activity is an indicator of less severe risk for lapse. The inverse relationship of FTND with amygdala activation and the reductions in all regions' effect size as predictors when controlling for FTND is consistent with this interpretation, suggesting that some of these regions' predictive ability is due to their relationship with severity of dependence. However, that the right ventral striatum was predictive beyond FTND suggests that there may be other elements of lapse risk that are indicated by activity in these regions beyond self-report measures of nicotine dependence. While this study found greater activity in these regions during smoking cues relative to neutral cues predicted better treatment response, prior studies using pre-treatment fMRI to predict smoking cessation treatment outcomes have found evidence that greater neural responding in these regions is associated with treatment failure (Janes et al. 2010; Versace et al. 2014) . It is possible that the discrepant findings might be explained by the influence of factors that moderate the degree of neural reactivity to smoking cues, such as individual demographic or smoking-related characteristics, or that the results could depend on study design features such as the specifics of the CR paradigm used. Another possibility is that the treatments in each of these studies played a role in this difference in directionality of the predictive findings. Although the interventions were ostensibly similar, there are still many potential differences, such as session duration, emphasis of treatment, treatment adherence or therapist training. Thus, it is possible that the current findings indicate that relatively high-intensity treatment is helpful in individuals demonstrating high levels of limbic/paralimbic activity in response to smoking cues. More broadly, these results illustrate the need for larger studies designed to focus on determining moderating factors for predicting treatment outcomes by using neuroimaging. Supporting Information accompanying the current study provides the treatment manual and adherence materials to facilitate potential treatment modality influences in future studies. In addition to methodological moderators, some variability may be due to the inherent difficulty in using laboratory paradigms to predict complex, real-world behaviors such as quitting smoking. Despite its robustness in eliciting self-reported craving, cue-elicited subjective craving has not demonstrated a consistent relationship to outcome in smoking cessation treatment (Perkins 2012) . In this study, self-reported craving in response smoking cues was not associated with outcome, suggesting that fMRI may be more sensitive than self-reported craving, although this work is still in its early stages.
These findings should be considered within the context of their limitations and strengths. Strengths of the study included biochemical verification of smoking abstinence and a well-standardized treatment protocol using empirically supported practices for the treatment of nicotine dependence and a focused analysis strategy targeting a small network of brain regions that have been consistently shown to respond during exposure to drug cues across users of several addictive substances. Among the most important considerations was the choice to focus on the regions reported by Kuhn and Gallinat, which have previously been identified as associated with the mesolimbic dopamine pathway and critical to the hedonic experience of addictive drugs. This was done to limit the scope of the study, thereby reducing the likelihood of spurious findings, and increase the interpretability of findings by focusing on regions sharing a putative core function in CR. Thus, this study had limited focus on one aspect of the neural response to drug cues. Studies addressing other neural systems involved in the response to drug/smoking cues (e.g. central executive network and default network) are needed to address questions about their efficacy in predicting treatment outcome. Another consideration is the metric of self-reported craving used. Because there has been substantially less research investigating neural response to CR paradigms as a predictor of outcome than self-reported craving a predictor of outcome, in designing the CR paradigm, we focused on maximizing collection of neural response. As a result, subjective ratings were assessed at the beginning and end of each run, not at the end of each block of smoking or neutral cues, preventing the calculation of average of smoking versus neutral cue block effects. Instead, it yielded a craving assessment that included the pre-CR and post-CR effects of smoking cues and neutral cues combined. While the use of post-CR craving is supported by prior research that suggests that neutral cues have little to no effect on self-reported cravings to smoke and that drug cues generate increases in craving that persist through neutral cues (i.e. carryover effects; Monti et al. 1987) , this approach does not capture self-reported craving at the same resolution as brain activation, making its use as a comparator limited. Despite this limitation, the form of self-reported craving used in this study still provides preliminary evidence of unique value of using fMRI to predict lapse and offers useful contextual information through its association with activation in the ventral striatum and dorsal anterior cingulate. However, findings surrounding self-reported craving in this study should be interpreted with caution until replicated with higher resolution measures of self-reported craving. Lastly, while lower levels of activation during smoking cues relative to neutral cues predicted lapse in this study, at the group level, significant differences in activation between smoking and neutral cues were found in only one of the three ROIs that predicted lapse (caudal ACC). This may potentially be because the meta-analysis used to identify the a priori ROIs had substantially greater statistical power, indicating the value of using meta-analyses in ROI selection. In addition, in the context of treatment response, these patterns may be present because lapseprone individuals exhibit diminished response to smoking cues in the striatum and amygdala and most participants in the current study lapsed at some point, leading to a lack of significant difference at the group level. However, hyperactivity during neutral cues in the striatum and amygdala in lapse-prone individuals may also play a role, as individual's exhibiting severe withdrawal may be triggered even by stimuli not overtly related to smoking. These interpretations are not mutually exclusive, and both would be consistent with the incentive-habit model, which states that highly dependent individuals smoke in response to bodily cues (like withdrawal) rather than external stimuli. In fact, because no regional activations during individual conditions predicted lapse (i.e. smoke versus baseline and neutral versus baseline), both interpretations are likely true to some degree.
Acknowledging these considerations, this study nonetheless provides evidence that pre-treatment neural response to smoking cues in limbic/paralimbic brain regions typically associated with response to smoking cues and craving is positively associated with an individual's ability to abstain from smoking as part of an organized smoking cessation attempt. Consequently, this study's findings provide support to the incentive-habit model of drug addiction (Mogg et al. 2005; Everitt & Robbins 2013) by suggesting that reductions in neural responsivity to smoking cues in brain regions associated with incentive salience are associated with an inability to abstain from smoking in dependent smokers in treatment. Clinically, this implies that for smokers who have transitioned from incentive learning and more deliberative cognitive processing to having habit learning and automatized drug seeking, smoking cessation is more difficult. Refining these relationships and further disentangling the neural predictors of smoking cessation outcome remains a critical priority for future studies.
